<DOC>
	<DOCNO>NCT02180334</DOCNO>
	<brief_summary>The aim study investigate effect combine administration mosapride modulator gastrointestinal motility DPP-4 inhibitor secretion gut hormone glucagon-like peptide-1 ( GLP-1 ) gastric inhibitory polypeptide ( GIP ) , oral glucose tolerance . Additionally , change lipid profile insulin secretion also assess .</brief_summary>
	<brief_title>The Effect Combination Mosapride DPP-4 Inhibitor Plasma Concentration Incretin Hormones</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , cross-over study . After screen enrollment , participant take 5 mg linagliptin day one week run-in period ( Day 1 Day 7 ) . Randomization do Day 8 assign participant either mosapride arm placebo arm . If subject assign mosapride arm , mixed meal tolerance test ( MMTT ) perform take mosapride linagliptin . If subject assign placebo arm , he/she take placebo instead mosapride MMTT . On Day 9 , subject cross arm MMTT proceed medication depend arm . Gastric empty time measurement paracetamol do along MMTT . Plasma incretin hormone level two arm compare .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>type 2 diabetes mellitus BMI &lt; 35 kg/m2 HbA1c 6.5~8.0 % lifestyle modification , 6.0~8.0 % take oral antidiabetic drug ( ) . lifestyle modification oral antidiabetic therapy ( sulfonylurea , biguanides , thiazolidinediones , alphaglucosidase inhibitor , DPP4 inhibitor ) Who read sign informed consent agreement chronic disease ( ) require medication diabetes mellitus type 1 diabetes mellitus history diabetic ketoacidosis insulin therapy require insulin therapy history gastrointestinal surgery exclude appendectomy , hernia repair hemorrhoid surgery serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) 2.5 time upper limit normal estimate glomerular filtration rate le 50 mL/min/1.73m2 genetic disorder associate digestion absorption galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption history hypersensitivity include anaphylaxis angioedema mosapride citrate , linagliptin , paracetamol ( acetaminophen ) history asthma associate aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) currently take drug prolong QT interval , include procainamide , quinidine , flecainide , sotalol , tricyclic antidepressant currently take anticholinergic atropine sulfate , scopolamine butylbromide childbearing lactate woman woman reproductive age disagree contraception proper method urine pregnancy test study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Gastric Emptying</keyword>
	<keyword>Gastrointestinal Motility</keyword>
	<keyword>Incretins</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>